{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:06:59Z","timestamp":1793452019175,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40291-025-00787-5","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:10:20Z","timestamp":1750385420000},"page":"553-561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Revakinagene Taroretcel: First Approval"],"prefix":"10.1007","volume":"29","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"issue":"1","key":"787_CR1","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/ijms23010386","volume":"23","author":"G Kaur","year":"2021","unstructured":"Kaur G, Singh NK. The role of inflammation in retinal neurodegeneration and degenerative diseases. Int J Mol Sci. 2021;23(1):386.","journal-title":"Int J Mol Sci"},{"key":"787_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2018.11.001","volume":"69","author":"SJ Gasparini","year":"2019","unstructured":"Gasparini SJ, Llonch S, Borsch O, et al. Transplantation of photoreceptors into the degenerative retina: current state and future perspectives. Prog Retin Eye Res. 2019;69:1\u201337.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"787_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/1673-5374.283498","volume":"16","author":"R Usategui-Martin","year":"2021","unstructured":"Usategui-Martin R, Fernandez-Bueno I. Neuroprotective therapy for retinal neurodegenerative diseases by stem cell secretome. Neural Regen Res. 2021;16(1):117\u20138.","journal-title":"Neural Regen Res"},{"key":"787_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.preteyeres.2012.11.002","volume":"34","author":"P Charbel Issa","year":"2013","unstructured":"Charbel Issa P, Gillies MC, Chew EY, et al. Macular telangiectasia type 2. Prog Retin Eye Res. 2013;34:49\u201377.","journal-title":"Prog Retin Eye Res"},{"key":"787_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jconrel.2024.01.063","volume":"367","author":"MB Appell","year":"2024","unstructured":"Appell MB, Pejavar J, Pasupathy A, et al. Next generation therapeutics for retinal neurodegenerative diseases. J Control Release. 2024;367:708\u201336.","journal-title":"J Control Release"},{"issue":"4","key":"787_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.ophtha.2018.09.041","volume":"126","author":"EY Chew","year":"2019","unstructured":"Chew EY, Clemons TE, Jaffe GJ, et al. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial. Ophthalmology. 2019;126(4):540\u20139.","journal-title":"Ophthalmology"},{"key":"787_CR7","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.2147\/OPTH.S373538","volume":"16","author":"KC Kedarisetti","year":"2022","unstructured":"Kedarisetti KC, Narayanan R, Stewart MW, et al. Macular telangiectasia type 2: a comprehensive review. Clin Ophthalmol. 2022;16:3297\u2013309.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"787_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4103\/1673-5374.314305","volume":"17","author":"V Maneu","year":"2022","unstructured":"Maneu V, Lax P, Cuenca N. Current and future therapeutic strategies for the treatment of retinal neurodegenerative diseases. Neural Regen Res. 2022;17(1):103\u20134.","journal-title":"Neural Regen Res"},{"key":"787_CR9","unstructured":"Neurotech Pharmaceuticals, Inc. ENCELTO (revakinagene taroretcel-lwey) implant, for intravitreal use: US prescribing information. 2025. https:\/\/www.fda.gov\/. Accessed 10 Mar 2025."},{"key":"787_CR10","unstructured":"US FDA. FDA roundup: March 7, 2025 [media release]. 7 Mar 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-roundup-march-7-2025."},{"key":"787_CR11","unstructured":"Neurotech Pharmaceuticals, Inc. Neurotech\u2019s ENCELTOTM (revakinagene taroretcel-lwey) approved by the FDA for the treatment of macular telangiectasia type 2 (MacTel) [media release]. 2025. https:\/\/www.neurotechpharmaceuticals.com\/."},{"key":"787_CR12","unstructured":"Neurotech Pharmaceuticals, Inc. Neurotech granted Fast Track Designations from the FDA for NT-501 in two indications: retinitis pigmentosa and dry age-related macular degeneration [media release]. 3 Sep 2008. http:\/\/www.neurotechusa.com."},{"key":"787_CR13","unstructured":"US FDA. Orphan drug designations and approvals. 2025. https:\/\/www.fda.gov\/. Accessed 1 Apr 2025."},{"issue":"10","key":"787_CR14","doi-asserted-by":"publisher","first-page":"6301","DOI":"10.1167\/iovs.14-14860","volume":"55","author":"WM Zein","year":"2014","unstructured":"Zein WM, Jeffrey BG, Wiley HE, et al. CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function. Invest Ophthalmol Vis Sci. 2014;55(10):6301\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11\u201312","key":"787_CR15","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1089\/ten.2004.10.1617","volume":"10","author":"CG Thanos","year":"2004","unstructured":"Thanos CG, Bell WJ, O\u2019Rourke P, et al. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Tissue Eng. 2004;10(11\u201312):1617\u201322.","journal-title":"Tissue Eng"},{"key":"787_CR16","unstructured":"Kauper K, Orecchio L, Nystuen A, et al. Continuous intraocular drug delivery lasting over a decade: ciliary neurotrophic factor (CNTF) secreted from Neurotech's NT-501 implanted in subjects with retinal degenerative disorders [abstract no. 3680]. Invest Ophthalmol Vis Sci. 2023;64(8)."},{"key":"787_CR17","unstructured":"Fera M. Effects of topically administered aminoglycoside antibiotics on NT-501 encapsulated cells in the vitreous [abstract no. 2200]. Invest Ophthalmol Vis Sci. 2024;65(7)."},{"key":"787_CR18","unstructured":"Selander L, Lanier P, Kauper K, et al. Hydrolytic stability and seal integrity evaluation of the NT-501 capsule and capsule component materials [abstract no. 3166]. Invest Ophthalmol Vis Sci. 2024;65(7)."},{"issue":"12","key":"787_CR19","doi-asserted-by":"publisher","first-page":"7484","DOI":"10.1167\/iovs.12-9970","volume":"53","author":"K Kauper","year":"2012","unstructured":"Kauper K, McGovern C, Sherman S, et al. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci. 2012;53(12):7484\u201391.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"787_CR20","first-page":"3292","volume":"43","author":"W Tao","year":"2002","unstructured":"Tao W, Wen R, Goddard MB, et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2002;43(10):3292\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"787_CR21","first-page":"936","volume":"51","author":"M Gillies","year":"2023","unstructured":"Gillies M. Two parallel, phase 3 randomised controlled trials of the NT-501 ciliary neurotrophic factor implant for macular telangiectasia type 2 [abstract]. Clin Experiment Ophthalmol. 2023;51(9):936.","journal-title":"Clin Experiment Ophthalmol"},{"key":"787_CR22","unstructured":"Neurotech Pharmaceuticals, Inc. Neurotech Pharmaceuticals, Inc. announces positive phase 3 topline results for NT-501 implant in macular telangiectasia type 2 [media release]. 2 Nov 2022. https:\/\/www.neurotechpharmaceuticals.com\/."},{"issue":"7","key":"787_CR23","first-page":"942","volume":"65","author":"A Dominguez","year":"2024","unstructured":"Dominguez A, Beykin G, Nunez M, et al. A randomized, sham controlled, masked phase II study for safety of intravitreal implantation of NT-501 encapsulated cell therapy for the treatment of glaucoma: adverse events and structural outcomes [abstract]. Invest Ophthalmol Vis Sci. 2024;65(7):942.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"787_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100298","volume":"3","author":"JL Goldberg","year":"2023","unstructured":"Goldberg JL, Beykin G, Satterfield KR, et al. Phase I NT-501 ciliary neurotrophic factor implant trial for primary open-angle glaucoma: safety, neuroprotection, and neuroenhancement. Ophthalmol Sci. 2023;3(3): 100298.","journal-title":"Ophthalmol Sci."},{"issue":"15","key":"787_CR25","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1073\/pnas.1018987108","volume":"108","author":"K Zhang","year":"2011","unstructured":"Zhang K, Hopkins JJ, Heier JS, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011;108(15):6241\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"787_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ajo.2013.03.021","volume":"156","author":"DG Birch","year":"2013","unstructured":"Birch DG, Weleber RG, Duncan JL, et al. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am J Ophthalmol. 2013;156(2):283-92.e1.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"787_CR27","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1097\/IAE.0000000000000064","volume":"34","author":"S Pilli","year":"2014","unstructured":"Pilli S, Zawadzki RJ, Telander DG. The dose-dependent macular thickness changes assessed by FD-OCT in patients with retinitis pigmentosa treated with ciliary neurotrophic factor. Retina. 2014;34(7):1384\u201390.","journal-title":"Retina"},{"issue":"4","key":"787_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ajo.2014.12.013","volume":"159","author":"EY Chew","year":"2015","unstructured":"Chew EY, Clemons TE, Peto T, et al. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial. Am J Ophthalmol. 2015;159(4):659-66.e1.","journal-title":"Am J Ophthalmol"}],"updated-by":[{"DOI":"10.1007\/s40291-025-00802-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000}}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00787-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00787-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:43:37Z","timestamp":1757191417000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00787-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["787"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00787-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40291-025-00802-9","asserted-by":"object"}]},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"30 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40291-025-00802-9","URL":"https:\/\/doi.org\/10.1007\/s40291-025-00802-9","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}